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Abstract
The live attenuated yellow fever (YF) vaccine has an excellent record of efficacy and one dose provides long-lasting
immunity, which in many cases may last a lifetime. Vaccination stimulates strong innate and adaptive immune responses,
and neutralizing antibodies are considered to be the major effectors that correlate with protection from disease. Similar to
other flaviviruses, such antibodies are primarily induced by the viral envelope protein E, which consists of three distinct
domains (DI, II, and III) and is presented at the surface of mature flavivirions in an icosahedral arrangement. In general, the
dominance and individual variation of antibodies to different domains of viral surface proteins and their impact on
neutralizing activity are aspects of humoral immunity that are not well understood. To gain insight into these phenomena,
we established a platform of immunoassays using recombinant proteins and protein domains that allowed us to dissect and
quantify fine specificities of the polyclonal antibody response after YF vaccination in a panel of 51 vaccinees as well as
determine their contribution to virus neutralization by serum depletion analyses. Our data revealed a high degree of
individual variation in antibody specificities present in post-vaccination sera and differences in the contribution of different
antibody subsets to virus neutralization. Irrespective of individual variation, a substantial proportion of neutralizing activity
appeared to be due to antibodies directed to complex quaternary epitopes displayed on the virion surface only but not on
monomeric E. On the other hand, DIII-specific antibodies (presumed to have the highest neutralizing activity) as well as
broadly flavivirus cross-reactive antibodies were absent or present at very low titers. These data provide new information on
the fine specificity as well as variability of antibody responses after YF vaccination that are consistent with a strong influence
of individual-specific factors on immunodominance in humoral immune responses.
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Introduction
The live-attenuated yellow fever (YF) vaccine based on the
17D virus strain is considered to be one of the most successful
vaccines ever produced [1,2]. Since its development in the
1930s by Max Theiler, several hundred million doses have been
administered and its effectiveness in protecting from disease has
been reported to be at least 90% [1]. Recent studies, including
systems biology approaches [3], analyzing innate, cellular and
humoral immune responses after YF vaccination indicate that
all arms of the immune system are activated, leading to a
polyfunctional response that is most likely essential for the long-
lasting immunity induced by this vaccine [3,4,5]. Despite the
broad immunological stimulation, there is strong evidence that
humoral immunity mediated by virus-neutralizing antibodies is
the primary effector mechanism of protection [1]. Such
antibodies may persist for more than 45 years and apparently
protect against all naturally occurring genotypes of YF virus
[1].
YF virus is the prototypic and name-giving member of the genus
flavivirus, family flaviviridae [6]. It is closely related to other
mosquito-borne and tick-borne human pathogens, the most
important of which are dengue, Japanese encephalitis, West Nile
and tick-borne encephalitis viruses [6]. Structural details of
flaviviruses have been elucidated for dengue, tick-borne enceph-
alitis (TBE), West Nile (WN), and Japanese encephalitis viruses
using X-ray crystallography and cryo-electron microscopy [7,8],
but no such data are yet available for YF virus. However, based on
the similarity of the structures determined for different flaviviruses
and their close molecular biological and even antigenic relation-
ships, it is justifiable to postulate that the structural organization of
YF virus particles as well as its constituting proteins follows the
same principles that are typical of flaviviruses in general (Figure 1).
Immature virions (Figure 1A, left panel) are assembled in the ER
and contain three structural proteins, designated as C (capsid),
prM (precursor of membrane) and E (envelope). These particles
contain 60 trimeric spikes of prM-E heterodimers and are secreted
through the exocytotic pathway of the cell [9]. In the acidic
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environment of the trans-Golgi network, prM is cleaved by furin
[10] and during this process the E protein is completely rearranged
to form a herringbone-like lattice of 90 E homodimers at the
surface of mature virions [11,12] (Figure 1A, right panel and
Figure 1B). Because of its functions in virus entry (cell attachment
and viral fusion in the endosome; [7,13]), the E protein is the
major inducer and target of virus neutralizing antibodies.
Neutralizing activity (albeit low) has also been reported for
antibodies against prM [14,15], which is consistent with the fact
that the maturation cleavage of prM is not always complete and
that partially mature (but already infectious) particles play a role in
flavivirus infections [16]. The overall structure of E is highly
conserved among all flaviviruses and consists of three character-
istically folded domains (DI, DII, and DIII), which are schemat-
ically depicted in Figure 1. Studies with other flaviviruses and
monoclonal antibodies have shown that antibodies to each of the
domains can lead to virus neutralization, although those directed
to DIII appeared to have the greatest specific neutralizing activity
[17]. The tip of DII contains a highly conserved sequence - the
fusion peptide (FP) loop - that is essential in membrane fusion and
contributes to the induction of broadly flavivirus cross-reactive
antibodies with no or relatively low neutralizing activity
[18,19,20].
Factors controlling the dominance of antibody responses to
different sites on protein antigens are ill-defined but can strongly
influence the breadth and functional activity of polyclonal immune
sera [21,22]. Studies on the molecular antigenic structure of
flaviviruses have shown that E protein domain-specific, domain
overlapping, subunit overlapping, and complex quaternary
epitopes can be targets of neutralizing antibody responses, both
in animals and humans (reviewed in [8]). Very little information,
however, exists with respect to the relative proportions of antibody
subsets and individual variations in polyclonal sera after infection
or vaccination. The mechanism of B cell stimulation cannot
distinguish between sites involved in virus neutralization and
‘decoy’ sites that induce only ‘junk antibodies’ [23,24,25], and
such variations can have a strong impact on the functional activity
of the humoral immune response. Thus, the primary objective of
this study was to dissect the polyclonal antibody response after YF
vaccination in a large panel of vaccinees and to obtain information
on the extent of individual variation as well as its possible
consequences for virus neutralization. For this purpose, we made
use of the modular organization of the flavivirus E protein and
established a platform of immunoassays on the basis of recombi-
nant E protein and its domain substructures (DIII and DI+II)
(Figure 1C). We provide evidence that the antibody response to
YF vaccination is subject to strong individual variation with
respect to the relative proportions of antibodies produced to the
domains of E as well as to prM. Importantly, this vaccine appears
to induce very little flavivirus cross-reactive antibodies that have
been previously shown to dominate immune responses to other
flavivirus infections [15,26,27,28]. Antibody depletion experiments
strongly suggest that a substantial proportion of the neutralizing
antibody response is directed to complex antigenic sites that are
not represented by the isolated E protein, but rather are
dependent on oligomeric interactions between these proteins at
the virion surface.
Results
Characteristics of YF vaccinees and sera
In this study, we analyzed serum samples from volunteers who
had been vaccinated with the live YF vaccine in Switzerland and
Germany between 0.5 and 42 years prior to sample collection.
Since another flavivirus (TBE virus) is endemic in both countries
and many people have been vaccinated against this antigenically
related virus, we made sure that none of YF vaccinees enrolled in
the study had a history of TBE vaccination by interrogation and -
as an additional control – by TBE neutralization tests (NT). There
was only one serum with a positive TBE NT titer for which we
were not able to identify his/her TBE vaccination history and
which was excluded from our analyses. The final cohort consisted
of 51 individuals which tested positive in YF-NT (titer $20) and
negative in TBE-NT (titer ,10) and had no history of TBE
vaccination. The basic characteristics of this cohort with respect to
age at vaccination, age at sample collection and time elapsed since
vaccination are summarized in Table 1 and displayed in
Figure 2A–C. These parameters were not homogeneously
distributed, reflecting the age-related travel behavior of YF
vaccinees of central Europe. As shown in Figure 2D, a significant
negative correlation was found between NT50 titers and the
interval of time since vaccination. No statistically significant
influence, however, was found with respect to the age at
vaccination by comparing the ,30 and .50 years old vaccinees
that had received the vaccine within 3 years before sample
collection (Figure 2E).
Quantification of antibody subsets in polyclonal sera and
their relative proportions
For dissecting the specificities of antibody populations present in
the 51 post-vaccination sera and the contribution of such antibody
subsets to virus neutralization, we produced the following set of C-
terminally strep- or His-tagged recombinant YF proteins as shown
in Figure 1C: 1. a C-terminally truncated soluble monomeric form
of YF E (YF sE-strep); 2. domains DI+II of YF E (YF DI+II-strep);
3. domain III of YF E as a fusion protein with thioredoxin (YF
DIII TR-His); and 4. a C-terminally truncated soluble form of YF
prM (YF prM-strep). To analyze the presence of flavivirus cross-
reactive antibodies, we used sE proteins from TBE virus (TBE sE-
strep) and WN virus (WN sE). Evidence for proper folding was
obtained in a number of control experiments, which are described
Author Summary
The live-attenuated yellow fever vaccine has been admin-
istered to more than 600 million people worldwide and is
considered to be one of the most successful viral vaccines
ever produced. Following injection, the apathogenic
vaccine virus replicates in the vaccinee and induces
antibodies that mediate virus neutralization and subse-
quent protection from disease. In principle, many different
antibodies are induced by viral antigens, but it is
becoming increasingly clear that only a subset of them is
capable of inactivating the virus, and some antibody
populations appear to dominate the immune response.
However, to date there has been very little information on
individual-specific variations of immunodominance and
how such variations can affect the functionality of
antibody responses. In our study, we addressed these
issues and analyzed the fine specificities of antibodies
induced by YF vaccination as well as the contribution of
different antibody subsets to virus neutralization in 51
vaccinees. We demonstrate an extensive degree of
individual variation with respect to immunodominance
of antibody populations and their contribution to virus
neutralization. Such variations can have an impact on
vaccine-mediated protection, and thus insight into this
phenomenon can provide leads for novel strategies in
modern vaccine design.
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in detail in the supporting Information (Figure S1, Text S1 and
S2).
Using these recombinant proteins, we established ELISAs that
were all highly sensitive and specific (see Supplemental materials,
Figure S2AB, Text S1 and S2) and – with the use of internal
standards - allowed us to quantify antibodies directed to E and its
substructures as well as to prM in relation to those measured in
virion ELISAs and virus neutralization assays (Figure S3, Text S1
and S2). The results obtained in these assays with the YF post-
vaccination sera from the 51 individuals are shown in Figure 3. All
of the sera were positive in the virion ELISA and neutralization
assay (with complete neutralization at low serum dilutions in all
instances), compared to 82% positives in the sE and DI+II
ELISAs, respectively. Remarkably, only 14% low positives were
observed in the ELISAs using YF DIII or sE of distantly related
flaviviruses (WN and TBE viruses), although the corresponding
assays had sensitivities similar to those of the YF sE and DI+II
ELISAs (see Figure S2A for YF DIII ELISA and Figure S2BC for
WN and TBE ELISAs). Antibodies to prM were somewhat
intermediate, with 57% of the post-vaccination sera being positive.
Statistical analyses showed highly significant positive correlations
(p,0.0001) between all of the units/titers measured in the
different antibody assays (Table 2).
Independent of the differences observed with respect to
antibody titers (at least in part due to the different time windows
between vaccination and blood sampling; Figure 2D), our primary
interest in this study was directed at individual-specific variations
in the composition of antibody specificities and their proportions
in post-vaccination sera as well as their possible influence on virus
neutralization. To identify such variations, we plotted the
reactivities in the virion ELISA (Figure 4A) against those of the
sE, DI+II and prM ELISAs (Figure 4B–D) as well as NTs
(Figure 4E). DIII-reactivities were not included because they were
mostly negative. This analysis revealed substantial deviations from
Figure 1. Schematic representation of flavivirus particles and YF virus antigens used in this study. (A) Schematic model of a flavivirus
particle. Left panel: immature virion, right panel: mature virion. The capsid contains the viral RNA and multiple copies of the C protein. The surface of
immature particles consists of 60 spikes composed of trimers of prM-E heterodimers. Mature particles are formed after prM cleavage and contain 90 E
homodimers. The structure of E was determined for soluble forms of E (sE) - schematically shown in the panel of mature virions - lacking the so-called
stem- and membrane anchor-regions. (B) Representation of the arrangement of E dimers at the surface of mature dengue 2 virions. Thirty rafts of
three parallel E dimers form a herringbone-like icosahedral shell. The figure was constructed using the coordinates of dengue 2 virus from the
VIPERdb Virus Particle Explorer (viperdb 1thd; http://viperdb.scripps.edu). (C) Schematic representations of recombinant yellow fever antigens. Color
code E: domain I – red, domain II – yellow, domain III – blue; fusion peptide (FP) - orange; stem – purple; transmembrane anchor – light grey. Color
code prM: ectodomain – green, transmembrane anchors – dark grey. Color code of recombinant protein tags: black. TR: thioredoxin. The asterisk
indicates the position of the mutation in the furin cleavage site of YF prM.
doi:10.1371/journal.ppat.1003458.g001
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the order of reactivities in the virion ELISA, providing evidence
for different antibody compositions of individual sera that also
affected their functional activities in virus neutralization. To
quantify the extent of this variation, we calculated the ratios of
antibody units obtained in sE, DI+II, and prM-ELISAs as well as
NT titers relative to virion ELISA units for each individual serum
sample. These ratios are shown in Figure 5, which reveals a
substantial degree of variation, especially in the case of the NT/
virion ELISA ratios. In the subunit ELISAs, sera yielding negative
results were omitted from these calculations and the real extent of
variation is most likely higher than displayed in the figure. In other
viral systems, the possibility of a selective decline of certain
antibody specificities has been reported. Since the time between
vaccination and sample collection varied substantially between
individuals and differences in the decline of antibody subsets
cannot be excluded a priori, we assessed the correlation between
the ratios shown in Figure 5 and the time elapsed since
vaccination. The Pearson correlation coefficients between these
parameters, however, were 0.07 to 20.17 (p values$0.3), showing
that there was no significant change in antibody composition of
post-vaccination sera over time.
Depletion analysis
To obtain information on the contribution of different antibody
populations to virus neutralization in individual sera, we conduct-
ed depletion analyses by removing distinct antibody subsets with
the recombinant YF antigens sE, DI+II, DIII, and prM bound to
magnetic beads. The complete removal of antibodies was
controlled by performing an ELISA with the antigen used for
depletion (Figure 6, left panels), and then the residual reactivity of
the depleted sera was analyzed in the virion ELISA (Figure 6,
middle panels) and NT (Figure 6, right panels) compared to sera
mock-depleted with magnetic beads only as the 100% control. A
set of 8 serum samples was selected for these analyses, which all
had relatively high NT titers and differed in their ratios of
reactivities with the recombinant antigens. As an example, the
original data of the depletion analyses for vaccinee 2 are provided
in Figure S4 which shows that the curves before and after
depletion were almost parallel. The characteristics of all 8
vaccinees (marked with asterisks in Figure 4) are summarized in
Table 3 and the results of depletion analyses are presented in
Figure 6. Depletion with DIII (Figure 6, panels C) did not result in
Figure 2. Characteristics of the YF post-vaccination cohort and sera. Distribution of (A) age at the time of vaccination, (B) age at the time of
sample collection, and (C) years between vaccination and sample collection. (D) Correlation of YF NT titers and years between vaccination and sample
collection. The Pearson correlation coefficients r and the P values are indicated. (E) Comparison of YF NT titers of young (,30 years of age at the time
of vaccination) and elderly (.50 years of age at the time of vaccination) vaccinees. Only individuals who were vaccinated within 3 years before
sample collection were included. The statistical analysis is provided at the top of the panel (t-test; ns, not significant).
doi:10.1371/journal.ppat.1003458.g002
Table 1. Characterization of cohort of YF vaccinees.
Number 51
Gender 27m/24f
Age at YF vaccination 36* (15–70)**
Age at sample collection 50* (20–87)**
Years after YF vaccination 2.58* (0.5–42)**
TBE NT Negative (NT titer ,10)
*median;
**range.
doi:10.1371/journal.ppat.1003458.t001
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any significant reduction of the virion ELISA- and NT-reactivities,
consistent with the low or negative titers measured in DIII ELISA
(compare Figure 3). In contrast, substantial proportions of
antibodies were removed by sE and DI+II from many (but not
all) serum samples, ranging from 25 to 59% of the virion ELISA
reactivity and 0 to 79% of the NT-activity (Figure 6, panels A and
B). In some instances, there was a good correlation between the
depletion measured in the virion ELISA and NT, and in other
cases substantial deviations were observed, which are specifically
addressed below. The depletion assays also confirmed the
induction of prM-specific antibodies by YF vaccination (ranging
from 12 to 37% of the total virion ELISA reactivity) but their
contribution to virus neutralization (ranging from 0 to 26%) was
not statistically significant (Figure 6D, right panel; p.0.05).
Overall, this analysis confirmed a high degree of individual
variation in the composition of post-vaccination sera with respect
to virion-specific and neutralizing antibodies.
Because of their distinctive patterns, the results obtained with
the sera of vaccinees 1 and 33 on the one hand and vaccinees 5
and 7 on the other are especially noteworthy. In the case of serum
from vaccine 33, almost half of the virion reactivity was removed
by depletion with sE (as well as DI+II); however, in contrast to
other sera this did not result in any significant reduction in
neutralizing activity. Since DIII-specific and prM-specific anti-
bodies also did not contribute to neutralization in this case, we
conclude that antibodies to subunit-overlapping (i.e., dimer-
specific) and/or herringbone-specific quaternary epitopes (but
not antibodies to the monomeric sE) were primarily responsible for
the neutralizing activity of this serum. The opposite was seen with
serum from vaccinee 1. Similar to serum from vaccinee 33,
approximately 50% of the virion reactivity was removed by sE and
DI+II, but in contrast, the neutralization effect was substantial and
accounted for more than 75% of the total neutralizing activity
(Figure 6A, right panel).
The similarity and excellent correlation of reactivities observed
in sE and DI+II ELISAs (Figure 4 and Table 2) was also confirmed
when sE- and DI+II-depleted sera were analyzed in the virion
ELISA (Figure 6A and B, middle panels). However, a significant
discrepancy was observed for NT of sera from vaccinees 5 and 7.
In both cases, approximately 65% of the total neutralizing activity
Figure 3. ELISA reactivities and NT titers of YF post-vaccination sera. Antibody ELISA reactivities against different antigens are expressed as
IgG units. Dashed lines indicate the cut-off in each assay.
doi:10.1371/journal.ppat.1003458.g003
Table 2. Correlation of results obtained in different YF antibody assays (Pearson correlation coefficients).
Assay sE ELISA DI+II ELISA prM ELISA virion ELISA
sE ELISA
DI+II ELISA 0.96 (p,0.0001)
prM ELISA 0.84 (p,0.0001) 0.88 (p,0.0001)
virion ELISA 0.89 (p,0.0001) 0.93 (p,0.0001) 0.90 (p,0.0001)
NT 0.58 (p,0.0001) 0.63 (p,0.0001) 0.59 (p,0.0001) 0.65 (p,0.0001)
doi:10.1371/journal.ppat.1003458.t002
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Figure 4. ELISA reactivities and NT titers of YF post-vaccination sera ordered according to their virion ELISA reactivities. ELISA IgG
units obtained with YF virion (A), YF sE (B), YF DI+II (C) and prM (D). (E) YF virus-specific NT titers. Dashed lines indicate the cut-off in each assay.
Numbers and asterisks on top of the columns indicate sera of vaccinees selected for depletion analyses (Table 3 and Figure 6).
doi:10.1371/journal.ppat.1003458.g004
Yellow Fever Vaccination and Antibody Specificity
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was depleted by sE, whereas DI+II had no measurable effect.
Since there was no evidence for DIII antibodies in these sera
(Figure 6C), it is likely that antibodies to epitopes at the junction
between DI and DIII (present in sE but not in DI+II) were
responsible for these results. From these data, we conclude that
individual vaccinees not only differ dramatically with respect to the
composition of their antibody subsets directed to different parts of
viral surface proteins, but also with respect to the contribution of
such subsets to virus neutralization.
Discussion
The primary goal of this study was to gain insight into individual
variations in fine specificities of the antibodies and their possible
impact on virus neutralization after YF vaccination. This was
accomplished by quantifying subsets of antibodies directed to
distinct domains of the viral envelope protein E and determining
their contribution to virus neutralization. Our data provide
evidence for extensive differences in the specificities and relative
proportions of antibody populations induced by YF vaccination in
different individuals. This conclusion is primarily based on the
observation that the ratios of reactivities in ELISAs with the
monomeric E, DI+II and prM relative to the virion ELISA
reactivities varied substantially (compare Figure 5). Substantial
variation was found in the ratio between virion ELISA reactivities
and neutralization titers, suggesting a strong influence of antibody
subset composition on the functional activity of individual sera.
Further confirmation of the observed heterogeneities was obtained
by the quantitative analysis of antibodies in sera depleted with
recombinant antigens. Specifically, depletion with the monomeric
sE resulted in a strongly diverging pattern of neutralizing activity
removed (ranging from 0 to 79%) which in several instances did
not match the reactivity pattern of the virion ELISA (compare the
panels in Figure 6 A), and similar differences were also observed in
depletions with DI+II. Our data not only demonstrate extensive
differences in the fine specificities of antibody subsets in post-
vaccination sera, but also that these heterogeneities can strongly
affect functional activities such as virus neutralization. It is likely
that these findings are related to cooperative and/or competitive
interactions between antibody populations directed to the same
target antigen but displaying different fine specificities, avidities
and concentrations. Such effects have been described in studies
with monoclonal antibodies [29,30,31] and were proposed for
explaining variations in the efficiency of polyclonal sera to
neutralize influenza virus [32] and HIV [31]. In the case of YF
and other flaviviruses, the phenomenon of virus breathing has to
be considered as an additional layer of complexity, because it
allows binding of antibodies to epitopes that are seemingly
inaccessible in a static model of virion structure but become
exposed through dynamic motions of the virion shell
[33,34,35,36,37,38]. Antibodies to such sites can thus contribute
to virus neutralization and increase the potential individual
variation.
Studies with dengue viruses as well as other flaviviruses have
shown that genotype- or strain-variations affecting individual
epitopes and/or the degree of virus maturation can have a
profound effect on the results of neutralization assays
[14,39,40,41,42]. Since the infecting strain is rarely known in
studies with post-infection sera, neutralization results generated
with a specific laboratory strain may be biased by such
phenomena. In this context, our study had the advantage of using
antigens in the ELISAs as well as the virus in neutralization assays
that were identical to the 17D virus strain used for immunization.
The variations observed can therefore be considered true
variations in fine specificities of antibodies for the same
immunogen in different individuals, which are not influenced by
possible strain-specific effects.
One important finding of our study is that a varying proportion
of neutralizing antibodies induced by YF vaccination in individuals
is apparently directed to complex epitopes found at the virion
surface only, but not on an isolated form of the monomeric E
protein. In all instances, only part of the total neutralizing activity
could be removed by sE depletion, suggesting that the residual
activity is due to antibodies specific for E dimer-dependent or even
more complex dimer-overlapping epitopes that are generated by
the herringbone-like quaternary arrangement of E dimers at the
virion surface (Figure 1B). Indeed, an epitope comprising residue
71 in DII and 155 in DI of the opposing E monomer was identified
as a dimer-specific epitope by the use of human monoclonal
antibody fragments derived by repertoire cloning from YF patients
[43]. E-dimer- and herringbone-dependent epitopes have also
been characterized for other flaviviruses using monoclonal
antibodies [44,45,46,47] and - in the case of post-infection dengue
sera - the majority of antibodies seemed to be directed against such
complex epitopes [48]. In some YF post-vaccination sera,
substantially different patterns of neutralizing activity were also
observed after depletion with DI+II compared to sE (Figure 6AB,
right panels). Since antibodies to DIII did not contribute to the
depletion results in these cases, it can be assumed that the
discrepancies observed were due to antibodies directed to epitopes
at the junction between DI and DIII.
In contrast to the high frequencies and titers of antibodies
against DI+II, only a very low proportion of the post-vaccination
sera had antibodies against DIII (only 14% were positive) and the
Figure 5. Extent of variation of antibody reactivities in YF post-
vaccination sera. The ratio of results obtained in the YF sE, YF DI+DII
and YF prM ELISA as well as YF NT relative to virion ELISA results was
calculated for all sera. Data are expressed as log2 of these ratios
multiplied by 100 and each of the circles represents the ratio obtained
for an individual serum.
doi:10.1371/journal.ppat.1003458.g005
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titers of positive sera were low compared to those against sE and
DI+II, although the assays had comparable sensitivities (Figure
S2A). Furthermore, depletion analyses did not reveal any
contribution of DIII antibodies to virus neutralization in a set of
8 selected serum samples (Figure 6). DIII-specific antibodies had
been shown to dominate humoral immune responses in the mouse
[27,49] and to exhibit a higher specific neutralizing activity than
antibodies to other sites in E [17]. As revealed in several recent
studies, however, DIII-specific antibodies appear to play only a
minor role in human antibody responses to flaviviruses (reviewed
in [8,50]). Our results are consistent with data on human immune
responses to dengue [26,51,52] as well as West Nile [27,45] virus
infections, which demonstrate that DIII-responses formed only a
very small proportion of the total antibody response in these
species and that most of the neutralizing activity was due to
antibodies directed to other sites in E [51,52].
Similar to the situation with DIII-specific antibodies, we also
found only very low frequencies and titers of broadly flavivirus
cross-reactive antibodies. Such antibodies were shown to recognize
epitopes around the highly conserved FP loop (Figure 1) and
usually do not contribute significantly to virus neutralization
[18,19,20]. Our data are consistent with previous reports on highly
type-specific antibody responses after primary YF vaccination
measured in hemagglutination inhibition assays and also in ELISA
[53,54] but differ from the antibody response to dengue virus
infections. In the latter case, FP-specific antibodies were shown to
make up a large proportion of the total antibody response [26,28].
The reasons for these discrepancies are presently unclear but may
Figure 6. ELISA and NT analyses of YF post-immunization sera after depletion with YF sE (panels A), YF DI+II (panels B), YF DIII
(panels C) and YF prM (panels D). Left panels: Percent reactivity in post-depletion sera, determined by ELISA with the depletion antigen. Middle
panels: Percent reactivity in post-depletion sera, determined by ELISA with the virion. Right panels: Percent reactivity in post-depletion sera,
determined by NT. Results are expressed as percent of the ELISA IgG units or NT titers of mock-depleted sera (control). The numbers above the
columns in the middle and right panels indicate the percentage of reactivities remaining after depletion. Asterisks indicate the significance of
difference in antibody reactivities between depleted and control sera (t-test). The error bars represent standard error of the means calculated from
the results of at least three independent assays. Identification numbers of vaccinees are indicated under the panels (compare with Table 3 and
Figure 4).
doi:10.1371/journal.ppat.1003458.g006
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be related to differences in the formation and/or structure of
partially immature particles during virus replication in dengue-
infected individuals and YF17D vaccinees. The degree of virus
maturation (i.e. cleavage of prM) has been shown to affect FP
exposure by the demonstration of enhanced accessibility to
antibodies [55] and thus can potentially have a profound effect
on post-infection antibody profiles.
In contrast to the low DIII- and FP-specific responses, a
substantial proportion (57%) of the YF vaccinees in our study had
antibodies to prM. Studies on prM responses after flavivirus
infections are still limited but Western blot analyses have detected
prM antibodies in dengue and JE post-infection sera [56], and a
surprisingly high proportion of human monoclonal antibodies
generated from dengue infected individuals were found to be prM-
specific and able to promote antibody-dependent enhancement of
infection [14,15,57]. In our depletion analysis, we found a
moderate (but not statistically significant) contribution of prM
antibodies to virus neutralization (Figure 6D, right panel), which is
consistent with the poor neutralizing activity of dengue virus prM
antibodies [14]. It is likely that these neutralization data are
strongly influenced by the maturation state of the virus used in the
assays [14,42] and therefore further studies using artificial viruses
with defined prM-content will be necessary to compare the extent
of prM-responses after different flavivirus infections as well as
assess their role in virus neutralization, infection enhancement and
protection.
In conclusion, our study demonstrates a high degree of
individual variability in the fine specificities of antibody responses
to YF vaccination which affects virus neutralization. It is currently
unclear, whether and to what extent such variations can impact
the protective efficacy of YF vaccination and are related to rare
but existing vaccination failures [2]. Our data are consistent with
the assumption that the phenomenon of antibody immunodomi-
nance is strongly influenced by individual factors that control the
selection of high-affinity B cell clones for antibody production, in
addition to possible structural factors intrinsic to the antigen. Such
individual variations have to be considered in structure-based
vaccine designs that attempt to target the immune response to the
most potent protective antigenic sites [58].
Materials and Methods
Human sera
Serum samples were collected from individuals 0.5 to 42 years
after YF vaccination at the Institute of Virology, University of
Duisburg-Essen, Germany, the Institute of Medical Virology,
University Clinic of Frankfurt, Germany, and the Division of
Infectious Diseases and Hospital Epidemiology, University Hos-
pital of Zuerich, Switzerland. In total, 51 serum samples with no
records of other flavivirus infections or vaccinations were sent to
the Department of Virology, Medical University of Vienna,
Austria for diagnostic analyses and were used anonymously in this
study.
Ethics statement
The studies were approved by the ethics committees of the
University of Duisburg-Essen, Germany, the University Clinic of
Frankfurt, Germany, the University Hospital of Zuerich, Switzer-
land, and the Medical University of Vienna, Austria.
Virus production
A suckling mouse brain suspension of the YF virus 17D-204
vaccine strain was used as an inoculum for propagating the virus in
Vero cells using Dulbecco’s Modified Eagle Medium (DMEM)
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supplemented with 0.1% bovine serum albumin (BSA). Cell
supernatants were harvested 72 h post-infection, clarified by
centrifugation at 10,000 g (30 min; 4uC), concentrated by
ultracentrifugation at 150,000 g (1 h; 4uC) and purified by rate
zonal sucrose gradient ultracentrifugation as described for TBE
virus [59]. The virus peak was identified by hemagglutination
assays using goose red blood cells at pH 6.4 as described by Clarke
and Casals [60].
Production of recombinant proteins
The sE (aa 1–397), DI-II (aa 1–294) and prM (aa 1–129)
proteins of YF virus 17D (GenBank accession number X03700), as
well as sE (aa 1–400) of TBE virus strain Neudo¨rfl (GenBank
accession number U27495) were produced in Drosophila
Schneider 2 (S2) cells using the pT389 vector (provided by
Thomas Krey and Felix Rey, Institut Pasteur, France), which
encodes the Drosophila export signal sequence BiP, an enteroki-
nase cleavage site and a double strep-tag. All of these proteins were
produced in soluble form by C-terminal truncations that removed
their membrane anchors. In the case of the YF prM protein, the
furin cleavage site was mutated to obtain unprocessed prM, as
previously described [61]. WN sE (aa 1–400) was produced in
Drosophila Schneider 2 (S2) cells using the pMTBip/V5-His
vector (Life Technologies), with a stop-codon introduced after the
sE-sequence to yield the expression of the protein without a His-
tag as previously described [49]. Transfection of S2 cells was
carried out with CaCl2 according to the manufacturer’s protocol
(Invitrogen) and blasticidin resistance was used for the selection of
stably transfected cells. Recombinant protein expression was
induced by CuSO4, and the supernatants were harvested 7 d
post-induction. Strep-tagged recombinant proteins were purified
using Strep-Tactin columns (IBA), - according to the manufac-
turer’s protocol, and the untagged WN sE protein was purified by
immunochromatography using the flavivirus cross-reactive anti-
body 4G2 (ATCC) as previously described [49].
DIII of YF virus 17D (aa 295–391 in E) was expressed in E. coli
BL-21 cells as a fusion protein with thioredoxin and a C-terminal
His tag using the pET 32a Xa/LIC vector (Novagen). In this
vector, the internal His-tag was removed from the expression
cassette by site-directed mutagenesis (Life Technologies), leaving
only the C-terminal His-tag [49]. The recombinant fusion protein
was purified from clarified bacterial cell lysates by Ni2+ affinity
chromatography (GE Healthcare Life Sciences) following the
manufacturer’s protocol.
Schematics of the YF recombinant proteins are shown in
Figure 1.
IgG ELISA
ELISAs for analyzing YF virus-specific antibodies were
performed essentially as previously described [18]. Briefly,
microtiter plates were coated overnight at 4uC with pre-
determined optimized dilutions of purified recombinant antigens
or virus in carbonate buffer (pH 9.6). Plates were blocked with
phosphate-buffered saline (PBS) pH 7.4 containing 2% lamb
serum for 20 min at 37uC. Threefold serial dilutions (starting at
1:100) of human sera were then added for 1 h at 37uC. Biotin-
labeled goat anti-human IgG (Pierce) together with Streptavidin–
Peroxidase (Sigma) was used for detection. Sera were analyzed in
at least three independent experiments and specific IgG was
quantified using human YF post-vaccination sera - arbitrarily
defined to contain 1000 IgG Units – as internal standards (see
Supporting information). Four dilutions of each sample were
analyzed and data points within the linear range of the standard
curves were used for determining IgG units. The cut-off was
determined in each test by including flavivirus-negative human
sera and set at the mean plus three standard deviations.
YF virus neutralization assay
Neutralization assays were carried out in baby hamster kidney
cells (ATCC BHK-21) using two-fold serial dilutions of sera (in
triplicates) - starting at a dilution of 1:20 – and the YF vaccine
virus propagated in suckling mouse brain. The serum samples
were incubated with 20–40 TCID50 virus for 1 h at 37uC before
the addition of cells, which were then incubated for three
additional days. After removal of cell supernatants, the cells were
fixed with 4% paraformaldehyde for 20 min at room temperature,
and treated with a Tris-buffer (50 mM Tris, 150 mM NaCl,
pH 7.6) containing 3% nonfat dry milk, 0.5% Triton X-100, and
0.05% Tween 20 for 30 min at 37uC. The YF virus-specific
monoclonal antibody 2D12 (ATCC) was then added and the fixed
cells were incubated for 1.5 h at 37uC. Bound antibodies were
detected with alkaline phosphatase-labeled anti-mouse IgG
(Sigma) and SigmaFast pNNp (Sigma) as a substrate. The
enzymatic reaction was stopped with 1.5 N NaOH after 30 min
and the absorbance was measured at 405 nm. Titers were
determined after curve fitting with a four-parameter logistic
regression (GraphPad Prism 5; GraphPad Software Inc.) using
50% of the absorbance in the absence of antibody as a cut-off
(NT50). Titers $20 were considered positive.
Antibody depletion assays
Antibody depletion was essentially performed as previously
described [49] using the ‘‘Dynabeads His-Tag Isolation&Pulldown
kit’’ (Life Technologies) for binding proteins containing a His-tag
and Strep-Tactin magnetic beads (Qiagen) for binding proteins
containing a strep-tag. Thirty micrograms of recombinant proteins
were incubated with 100 ml paramagnetic beads and divided into
three aliquots. After pelleting by magnetic force, the beads were
resuspended in a buffer according to the manufacturer’s instruc-
tions and incubated for 1 h at 37uC with a 1:5 dilution of serum.
The beads were pelleted by magnetic force and the depleted serum
was collected. To achieve quantitative depletion, this procedure
was performed three times. Absence of non-specific binding of the
antibodies to the beads was controlled by incubating sera with
unloaded beads.
Statistical analyses
Statistical analyses were conducted using GraphPad Prism 5
(GraphPad Software Inc.). Logarithmic transformations of data
were performed to obtain approximate normal distribution of IgG
arbitrary units and NT titers. Two-tailed t-tests were used to
compare the transformed data and Pearson correlation tests were
used to determine correlation coefficients. P values,0.05 were
considered statistically significant.
Supporting information
Supporting information includes four figures (Figures S1, S2,
S3, S4) and a description of these figures (Text S1 and S2).
Supporting Information
Figure S1 Characterization of recombinant antigens. (A) SDS-
PAGE of recombinant antigens under reducing (+b-mercaptoeth-
anol) conditions. (B) SDS-PAGE of untreated (2) and DMS cross-
linked (+) YF sE-strep and TBE sE-strep proteins. The positions of
the sE monomer (M) and dimer (D) are indicated. (C) Sucrose
gradient sedimentation analysis of the YF sE-strep (left panel) and
TBE sE-strep (right panel) at pH 8.0 and pH 6.0. The
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sedimentation direction is shown from left to right, and the
positions of the sE monomer (M) and dimer (D) are indicated. (D)
SDS-PAGE of non-treated (2) and PNGase F-treated (+) YF sE-
strep, YF DI+II-strep and YF prM-strep proteins. (E) Western blot
of non-reduced (2) and reduced (+) recombinant YF sE-strep, YF
DI+II-strep and YF fusion DIII-His using conformation-sensitive
monoclonal antibodies as well as non-reduced (2) and reduced (+)
YF prM-strep with a polyclonal rabbit serum.
(TIF)
Figure S2 Sensitivities and specificities of YF virion and
recombinant antigen ELISAs for the detection of YF virus-specific
antibodies. (A) Reactivity with the DIII-specific MAb 86.64. (B)
Reactivity with the cross-reactive fusion peptide loop-specific MAb
A1. (C) Reactivity with TBE virus post-vaccination sera.
(TIF)
Figure S3 ELISA reactivities of standard sera with YF virion (A),
YF sE (B), YF DI+II (C), YF DIII (D), YF prM (E), and WN sE (F).
Error bars represent standard deviations, which were calculated
from at least three independent experiments.
(TIF)
Figure S4 ELISA and NT analyses of serum from vaccinee 2
(Figure 6) after depletion with YF sE (A), DI+II (B), DIII (C) and
prM (D). Left panels: absorbance curves before and after
depletion, determined in ELISA with the depletion antigen.
Middle panels: absorbance curves before and after depletion,
determined in ELISA with the YF virion. Right panels:
Neutralization curves before and after depletion. Error bars
represent standard errors of the mean, which were calculated from
at least three independent experiments. All panels: red curves
indicate sera before depletion, grey curves mock depletions, green
curves sera after depletion, dashed grey lines cut-offs. IgG ELISA
units and NT titers before and after depletion were determined as
described in Materials and Methods.
(TIF)
Text S1 Text S1 describes the characterization of recombinant
proteins used in the study and the standardization of ELISAs with
these antigens.
(DOCX)
Text S2 Text S2 describes Materials and Methods pertaining to
data shown in the supporting figures.
(DOCX)
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